tyrosine has been researched along with Coronary Disease in 154 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.95) | 18.7374 |
| 1990's | 36 (23.38) | 18.2507 |
| 2000's | 112 (72.73) | 29.6817 |
| 2010's | 3 (1.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alvarez-Leite, JI; Benseñor, IM; Bruno, T; Dos Reis Menta, PL; Goulart, AC; Leocádio, PCL; Lotufo, PA; Quidim, AVL; Santos, IS | 1 |
| Chen, SL; Chen, YD; Chen, YG; Cheng, XS; Ge, JB; Han, YL; Jiang, TM; Li, JL; Li, Y; Liang, ZY; Liu, HW; Liu, ML; Ma, LK; Ma, YT; Wang, G; Wang, HY; Xie, Q; Yang, BS; Zhao, X; Zheng, XQ | 1 |
| Anderson, D; Blomberg, A; Boon, NA; Cassee, FR; Donaldson, K; Donovan, RJ; Fokkens, PH; Freney, EJ; Heal, MR; Leseman, DL; MacNee, W; Miller, MR; Mills, NL; Newby, DE; Robinson, SD; Sandström, T | 1 |
| Chang, HC; Chien, SW; Hu, CY; Lim, PS; Liu, CS; Pai, MA; Wu, MY; Wu, TK | 1 |
| Ewart, MA; Greig, FH; Kennedy, S; Oldroyd, KG; Wadsworth, RM; Watt, J | 1 |
| Bobek, J; Farmer, J; Lakiss, N; Lakkis, N | 1 |
| Califf, RM; Kandzari, DE | 1 |
| Baker, CS; Bonser, RS; Camici, PG; Dutka, DP; Hall, RJ; Pagano, D; Pitt, M; Polak, JM; Rimoldi, O | 1 |
| Bonz, AW; Ertl, G; Harre, K; Held, S; Kochsiek, N; Lengenfelder, B; Meesmann, M; Neyses, L; Schanzenbächer, P; Strotmann, J; Turschner, O; Voelker, W; Wacker, C; Waller, C | 1 |
| Bigonzi, F; Borzak, S; Cohen, M; Frey, MJ; Harris, K; Lis, J; Mukherjee, R; Senatore, F; Théroux, P; Van Mieghem, W; White, HD | 1 |
| Brener, SJ; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Murphy, SA | 1 |
| Batchelor, WB; Califf, RM; Cantor, WJ; Davidian, M; DiBattiste, PM; Dillard, P; Gretler, D; Harrington, RA; Huang, Y; Larsen, RL; Mantell, RM; Ohman, EM; Sketch, MH; Tcheng, JE; Tolleson, TR; Zhang, D; Zidar, JP | 1 |
| Cohen, M | 1 |
| Braunwald, E; Cannon, CP; DiBattiste, PM; Januzzi, JL; Murphy, S; Weintraub, W | 1 |
| Aggarwal, A; Aguirre, F; DiBattiste, PM; Herrmann, HC; Kabbani, SS; Lakkis, N; Schneider, DJ; Wan, Y | 1 |
| Berdan, L; Califf, RM; Dyke, C; Gallup, D; Harrington, RA; Lauer, MS; Mahaffey, KW; Mänttäri, M; Moliterno, DJ; Mukherjee, D; Pieper, KS; Roe, MT; Topol, EJ; White, HD; Yadav, JS | 1 |
| Aggarwal, A; Aguirre, F; DiBattiste, PM; Herrmann, HC; Kabbani, SS; Lakkis, N; Lo, MW; Schneider, DJ; Yin, KC | 1 |
| Ioannidis, JP; Karvouni, E; Katritsis, DG | 1 |
| Armstrong, PW; Califf, RM; Christenson, RH; Fu, Y; Harrington, RA; Hasselblad, V; Kaul, P; Mahaffey, KW; Newby, LK; Ohman, EM; Topol, EJ; Van de Werf, F | 1 |
| DiBattiste, PM; Jang, Ik; Januzzi, JL; Sabatine, MS; Servoss, SJ; Theroux, P; Wan, Y | 1 |
| Aguanno, JJ; Glover, EN; Schumacher, JR; Schussler, JM; Vish, NA; Wheelan, KR; Wissinger, LA | 1 |
| Armstrong, PW; Califf, RM; Fu, Y; Harrington, RA; Hersi, A; Mahaffey, KW; Van de Werf, F; Wong, B | 1 |
| Bhapkar, MV; Califf, RM; Davis, CG; Granger, CB; Harrington, RA; Hochman, JS; Moliterno, DJ; Newby, LK; Simes, RJ; Topol, EJ; Van de Werf, F | 1 |
| Bonz, AW; Ertl, G; Held, S; Jacobs, M; Lengenfelder, B; Strotmann, J; Voelker, W | 1 |
| Brown, DL; Green, SJ; Kaplan, RC; Ravi, KL; Sanborn, TA; Sherman, W; Slater, JN; Vakili, BA | 1 |
| Cannon, CP; Demopoulos, LA; DiBattiste, PM; Gibson, CM; Lorenz, DP; Marble, SJ; Murphy, SA; Pinto, DS | 1 |
| Boersma, E; Westerhout, CM | 2 |
| Auer, J; Berent, R; Eber, B; Lassnig, E; Maurer, E; Weber, T | 1 |
| Alemao, E; Bakhai, A; Ben-Joseph, R; Collinson, JR; Flather, MD; Itzler, R; Normand, C; Stevens, W | 1 |
| Antman, EM; Bates, ER; Cohen, M; Every, NR; Ferguson, JJ; Harrington, RA; Pepine, CJ; Theroux, P | 1 |
| Boden, WE; Cannon, CP; Januzzi, JL; Theroux, P | 1 |
| Besta, F; Gawaz, M; Massberg, S; Mueller, I; Thomas, P | 1 |
| Merlini, PA; Rossi, ML | 1 |
| Aydin, M; Bilge, M; Gursurer, M; Ozdemir, H; Ozeren, A; Savranlar, A | 1 |
| Baglini, R; Capuano, C; Danzi, GB; Sesana, M | 1 |
| Antman, EM; Braunwald, E; Cannon, CP; Demopoulos, LA; DiBattiste, PM; Giugliano, RP; McCabe, CH; Morrow, DA; Murphy, SA; Sabatine, MS; Weintraub, WS | 1 |
| Corominas, N; Ferrer, E; Ortiz, J; Perez, J; Ribas, J; Sanz, G | 1 |
| De Caterina, R; Zimarino, M | 1 |
| Chang, Y; Choi, CJ; Gimelli, G; Harding, S; Inglessis, I; Jang, IK; Walters, D; Wong, P | 1 |
| Ferrari, E; Menabue, L; Saladini, M | 1 |
| Brouse, SD; Wiesehan, VG | 1 |
| Bilheimer, DW; Blazing, MA; Brady, WE; Braunwald, E; Califf, RM; de Lemos, JA; Fox, KA; Lewis, EF; Palmisano, J; Pfeffer, M; Ramsey, KE; White, HD; Wiviott, SD | 1 |
| Atwater, BD; Mahaffey, KW; Roe, MT | 1 |
| Ahn, YK; Cho, JG; Hong, SN; Hong, YJ; Jeong, MH; Kang, DK; Kang, JC; Kim, JH; Kim, KH; Kim, W; Lee, SH; Lee, YS; Lim, JH; Lim, SY; Moon, Y; Park, HW; Park, JC; Rhew, JY; Yun, KH | 1 |
| Chambers, CE; Demers, LM; Hartman, G; King, N; Kozak, M; McCann, J; McNulty, PH; Scott, S; Sinoway, LI | 1 |
| Baysan, O; Erinc, K; Isik, E; Ozkan, M; Sag, C; Uzun, M; Yokusoglu, M | 1 |
| Chang, ST; Cheng, NJ; Chung, CM; Yang, TY | 1 |
| Chun, KJ; Hong, TJ; Jeong, JH; Kim, JH; Park, YH; Shin, YW | 1 |
| Biscione, C; Crea, F; De Vita, M; Maria Leone, A; Mongiardo, R; Niccoli, G; Rebuzzi, A | 1 |
| Shanmugam, G | 1 |
| Dunkley, S; Evans, S; Gaudry, L; Jepson, N | 1 |
| Angioli, P; Baldassarre, S; Bolognese, L; Burali, A; Cosmi, F; Ducci, K; Falsini, G; Liistro, F; Taddei, T; Tarducci, R | 1 |
| Andreadou, I; Georgiadou, P; Iliodromitis, EK; Kremastinos, DT; Kyrzopoulos, S; Mademli, K; Markantonis-Kyroudis, S | 1 |
| Cohen, DJ; Hu, T; McClure, R; Moliterno, DJ; Mukherjee, D; Roffi, M; Shishehbor, MH; Stone, GW; Topol, EJ | 1 |
| Buckland, R; Judge, HM; Sastry, P; Siotia, A; Storey, RF | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; de Lemos, JA; Morrow, DA; Rifai, N; Sabatine, MS; Shui, A; Wiviott, SD | 1 |
| Jennings, LK | 1 |
| Münzel, TF; Post, F | 1 |
| Berger, P; Blankenship, JC; Herrmann, H; Kalyanasundaram, A; McClure, R; Moliterno, D | 1 |
| Topaz, O | 1 |
| Holmes, CE; Madsen, NJ; Schneider, DJ; Serrano, FA; Sobel, BE | 1 |
| Wu, RR; Xu, XM | 1 |
| Bolli, R; Davenport, NJ; Epstein, SE; Goldstein, RE | 1 |
| Ambrose, J; Cohen, M; Fitzpatrick, V; Herrmann, HC; Kereiakes, DJ; Kleiman, NS; McKee, DB; Palabrica, T; Rodriguez, S; Sax, FL; Sutton, JM; Weaver, WD | 1 |
| Verheugt, FW | 1 |
| Alvarez, RJ; Dang, CV; Gips, SJ; Goldschmidt-Clermont, PJ; Hoang, AT; Hruban, RH; Milliken, EE; Moldovan, N; Silverman, HS; Wilhide, CC | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Adgey, AA | 2 |
| Ferguson, JJ; Lau, TK | 1 |
| Armstrong, PW; Braunwald, E; Califf, RM; Gibler, WB; Hamm, CW; Maseri, A; Simoons, ML; Van de Werf, F | 1 |
| Abe, J; Deguchi, J; Hara, K; Ikari, Y; Kurokawa, K; Ohno, M; Takuwa, Y; Tamura, T | 1 |
| Albala, A; Barbone, A; Cannon, PJ; Michler, RE; Ming, M; Ravalli, S; Szabolcs, M | 1 |
| Cohen, DJ; Deckelbaum, LI; Gibson, CM; Goel, M; Harris, KE; King, SB; Piana, RN | 1 |
| Clem, JR; Falls, S | 1 |
| Lindenfeld, J | 1 |
| Lincoff, AM | 1 |
| Kleiman, NS; Ramanathan, A | 1 |
| Alexander, JH; Harrington, RA | 1 |
| Goa, KL; McClellan, KJ | 1 |
| Tcheng, JE | 2 |
| Al-Mousa, EN; Arshad, MN; Campsey, M; Gandhi, R; Gibson, CM; Marble, SJ; Mattson, S; Mesley, R; Moynihan, JL; Murphy, S; Ryan, KA; Swanson, J | 1 |
| Kaluza, G; Kleiman, NS; Mazur, W | 1 |
| Hillegass, WB; Newman, AR; Raco, DL | 1 |
| Phillips, J; Stouffer, GA; Subbarao, VD | 1 |
| Adgey, AA; Mathew, TP | 1 |
| Dunn, A | 1 |
| Harrington, RA | 1 |
| Juran, NB | 1 |
| Dyke, CM | 1 |
| Boccuzzi, SJ; Burnette, J; Cohen, DJ; Cook, JR; Culler, S; Kosinski, AS; Weintraub, WS | 1 |
| Deu, A; Goldmann, B; Hamm, CW; Heeschen, C; Langenbrink, L; White, HD | 1 |
| Bell, DM | 1 |
| Abbottsmith, CW; Broderick, T; Howard, WL; Kereiakes, DJ; Martin, LH; McDonald, M; Roth, EM; Schneider, J; Shimshak, T; Whang, DD | 1 |
| Galli, M; Maggioni, AP; Tavazzi, L; Vassanelli, C | 1 |
| Blennerhassett, J; Burnett, JR; McConnell, W; O'Leary, PC; Vasikaran, SD | 1 |
| Agostoni, P; Biondi-Zoccai, GG | 1 |
| Califf, RM; Lincoff, AM; Topol, EJ | 1 |
| Byrne, KH; Hanlon, SJ; MacCallum, EM | 1 |
| Ball, S; Becker, RC; Li, Y; Spencer, FA | 1 |
| Chadow, HL; Giarraffa, L; Gunsburg, MY; Hauptman, RE; Rafii, SE; Strom, JA; VanAuker, M | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Rosales, OR; Schroth, G; Sdringola, S; Smalling, RW; Westbrook, LA | 1 |
| Blankenship, JC; Frey, CM; Memon, MA; Menapace, FJ; Wood, GC | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Holmes, DR | 1 |
| Chae, CU; Giugliano, R; Hahn, SS; Jang, IK; Januzzi, JL; Lewandrowski, K; Theroux, P | 1 |
| Blankenship, JC; Iliadis, EA | 1 |
| Shepard, RW | 1 |
| Agustí, A; Araujo, R | 1 |
| Deckelbaum, LI; Dodge, JT; Dotani, I; Gibson, CM; Goel, M; King, SB; Marble, SJ; Murphy, SA | 1 |
| Droullé, C; Garnotel, R; Hézard, N; Metz, D; Nguyen, P; Potron, G | 1 |
| Ferguson, JJ | 1 |
| Lakkis, NM; Nguyen-Ho, P | 1 |
| Berkowitz, SD | 1 |
| Brown, DL; Chang, CJ; Fann, CS | 1 |
| Danchin, N | 1 |
| Gawaz, M; Hochholzer, W; Neumann, FJ; Pogatsa-Murray, G; Schömig, A | 1 |
| Goldmann, BU; Hamm, CW | 1 |
| Holmes, MB; Kabbani, SS; Schneider, DJ; Sobel, BE; Terrien, CM; Watkins, MW | 1 |
| Ambrose, JA; Barua, RS; Coppola, J; Dominguez, A; Doss, R; Duvuri, S; Geagea, JM; Giedd, K; Hawkey, MC; Nguyen, TH; Palla, V; Saha, DC | 1 |
| Nurden, P | 1 |
| Proimos, G | 1 |
| Armstrong, PW; Califf, RM; Christenson, RH; Harrington, RA; Hasselblad, V; Moliterno, DJ; Newby, LK; Ohman, EM; Pfisterer, M; Topol, EJ; Van De Werf, F; White, HD | 1 |
| Bertrand, M; Cohen, DJ; Cohen, EA; Demopoulos, L; DiBattiste, PM; Grines, CL; Herrmann, HC; Moliterno, DJ; Neumann, FJ; Powers, ER; Stone, GW; Topol, EJ | 1 |
| Throckmorton, DC | 1 |
| Boden, WE; McKay, RG | 1 |
| Stone, GW | 1 |
| Ali, M; Carville, D; George, S; Guyer, K; Lakkis, NM; Thomas, E | 1 |
| Kurz, HI; Lasala, JM; Taniuchi, M | 1 |
| Bertel, O; Genoni, M; Maloigne, M; Turina, M; Zeller, D | 1 |
| Chae, CU; Jang, IK; Januzzi, JL; Sabatine, MS | 1 |
| Bala, M; Lage, MJ; McCollam, PL | 1 |
| Anderson, HV; Assali, AR; Fujise, K; Ghani, M; Hale, S; Moustapha, A; Rosales, OR; Salloum, J; Schroth, G; Sdringola, S; Smalling, RW | 1 |
| Bertrand, M; Braunwald, E; Hamm, CW | 1 |
| Galli, M; Vassanelli, C | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Houghton, AR; Hudson, I; Patel, M | 1 |
| Chew, DP; Moliterno, DJ | 1 |
| Antman, EM; Braunwald, E; McCabe, CH; Morrow, DA; Snapinn, SM; Theroux, P | 1 |
| SoRelle, R | 1 |
| Aggarwal, A; DiBattiste, PM; Kabbani, SS; Schneider, DJ; Sobel, BE; Terrien, EF | 1 |
| Kondo, K; Umemura, K | 1 |
| Adamian, M; Collins, MB; Dangas, G; Iakovou, I; Kobayashi, Y; Lansky, AJ; Leon, MB; Mehran, R; Moses, JW; Polena, S; Roubin, GS; Stone, GW | 1 |
| Leclerc, JR | 1 |
| Moliterno, DJ; Topol, EJ | 1 |
| Balcells Comas, S; Ferrer Codina, I; García Giralt, N; Grinberg Vaisman, D; Mainou Cid, C; Mainou Pintó, A; Meco López, JF; Pintó Sala, X; Vilaseca Buscà, MA | 1 |
| Johnson, DA; Kirby, DA; Lown, B; Pinto, J; Zhao, S | 1 |
| Agostoni, A; Fiorelli, G; Marinari, M; Radice, F; Stabilini, R | 1 |
48 review(s) available for tyrosine and Coronary Disease
| Article | Year |
|---|---|
TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
Defining optimal therapy for the thrombolysis-ineligible patient.
Topics: Acute Disease; Coronary Disease; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Myocardial Reperfusion; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombolytic Therapy; Tirofiban; Tyrosine | 2002 |
Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Randomized Controlled Trials as Topic; Risk; Stents; Survival Analysis; Tirofiban; Tyrosine | 2003 |
Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Evaluation; Eptifibatide; Guidelines as Topic; Humans; Immunoglobulin Fab Fragments; Incidence; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
[Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Topics: Abciximab; Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Controlled Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Emergencies; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Time Factors; Tirofiban; Tyrosine | 2003 |
Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Topics: Abciximab; Acute Disease; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Assessment; Syndrome; Tirofiban; Tyrosine | 2003 |
[Role of GP IIb/IIIa blockers in clinical cardiology].
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2003 |
Glycoprotein IIb-IIIa antagonists in non-ST elevation acute coronary syndromes and percutaneous interventions: from pharmacology to individual patient's therapy: part 1: the evidence of benefit.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Comorbidity; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2004 |
Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2004 |
Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Contraindications; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Risk Factors; Tirofiban; Tyrosine | 2005 |
Tirofiban and emergency coronary surgery.
Topics: Acute Disease; Administration, Oral; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Emergencies; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Postoperative Hemorrhage; Thrombocytopenia; Tirofiban; Tyrosine | 2005 |
Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2005 |
[Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
Topics: Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Disease; Coronary Thrombosis; Diabetes Complications; Drug Therapy, Combination; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Renal Insufficiency; Risk Factors; Syndrome; Ticlopidine; Tirofiban; Troponin; Tyrosine | 2006 |
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Eptifibatide; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
New antiplatelet agents for acute coronary syndromes.
Topics: Abciximab; Acetates; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 1998 |
An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Atherectomy, Coronary; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary revascularization.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angina, Unstable; Angioplasty; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Myocardial Ischemia; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1998 |
Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Topics: Acetates; Acute Disease; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 1998 |
Tirofiban. A review of its use in acute coronary syndromes.
Topics: Acute Disease; Coronary Disease; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Tirofiban; Tissue Distribution; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Antiplatelet therapy for treatment of acute coronary syndromes.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine; Vascular Patency | 1999 |
Economic issues in glycoprotein IIb/IIIa receptor therapy.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Drug Costs; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 1999 |
Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Angina, Unstable; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Clinical trials of IIb/IIIa receptor blockers in patients undergoing angioplasty.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Safety; Tirofiban; Tyrosine | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Minimizing bleeding complications of percutaneous coronary intervention and glycoprotein IIb-IIIa antiplatelet therapy.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Aspirin; Catheterization, Peripheral; Coronary Disease; Coronary Thrombosis; Eptifibatide; Femoral Artery; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Revascularization; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Blood Platelets; Coronary Artery Bypass; Coronary Disease; Coronary Thrombosis; Eptifibatide; Fibrinolytic Agents; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Incidence; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Safety; Tirofiban; Tyrosine | 1999 |
Analysis of number needed to treat and cost of platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary interventions and acute coronary syndromes.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine; Vascular Surgical Procedures | 1999 |
Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Coronary Disease; Drug Therapy, Combination; Electrocardiography; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
[The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Topics: Acute Disease; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Syndrome; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
Topics: Abciximab; Acetates; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Myocardial Infarction; Patient Selection; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Recurrence; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis of major clinical trials.
Topics: Abciximab; Acetates; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Incidence; Infusions, Intravenous; Intracranial Hemorrhages; Odds Ratio; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine | 2000 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein receptor site blockade in coronary artery disease.
Topics: Abciximab; Angina, Unstable; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Pharmacology: antiplatelet and antithrombin therapy in acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Antithrombins; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2000 |
[Platelet-leukocyte interactions in coronary heart disease: pathophysiology, clinical relevance, pharmacological modulation].
Topics: Abciximab; Angina Pectoris; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Platelets; CD18 Antigens; Chemotaxis, Leukocyte; Coronary Artery Bypass; Coronary Disease; Cytokines; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Leukocytes; Ligands; Macrophage-1 Antigen; Membrane Glycoproteins; Models, Biological; Myocardial Infarction; Neutrophils; P-Selectin; Platelet Adhesiveness; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombospondins; Tirofiban; Tyrosine | 2000 |
Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease.
Topics: Abciximab; Administration, Oral; Aged; Angioplasty; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Sensitivity and Specificity; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
Current knowledge of the platelet glycoprotein IIb/IIIa receptor antagonists for the treatment of coronary artery disease.
Topics: Abciximab; Acetates; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Coronary Artery Bypass; Coronary Disease; Drug Approval; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Mice; Multicenter Studies as Topic; Myocardial Ischemia; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Recurrence; Safety; Single-Blind Method; Stents; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; United States; United States Food and Drug Administration | 2000 |
Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[GPIIb-IIIa inhibitors].
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors.
Topics: Abciximab; Adenosine Diphosphate; Amino Acid Chloromethyl Ketones; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Interactions; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Oligopeptides; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Proteins; Receptors, Thrombin; Thrombin; Tirofiban; Tyrosine | 2001 |
Acute coronary syndrome without ST elevation: implementation of new guidelines.
Topics: Abciximab; Algorithms; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Electrocardiography; Europe; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Risk Factors; Tirofiban; Troponin; Tyrosine; United States | 2001 |
GP IIb/IIIa inhibitors in coronary artery disease management: what the latest trials tell us.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Time Factors; Tirofiban; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: comparison with the monoclonal antibody abciximab.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Tirofiban; Tyrosine | 2002 |
Platelet glycoprotein IIb/IIIa antagonists: lessons learned from clinical trials and future directions.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Integrins; Peptides; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
41 trial(s) available for tyrosine and Coronary Disease
| Article | Year |
|---|---|
Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease.
Topics: C-Reactive Protein; Cardiovascular System; Coronary Disease; Cross-Over Studies; Dinoprost; Double-Blind Method; Fibrinolysis; Humans; Inhalation Exposure; Male; Middle Aged; Particulate Matter; Tyrosine; Vasomotor System | 2008 |
The effect of reactive oxygen species on whole blood aggregation and the endothelial cell-platelet interaction in patients with coronary heart disease.
Topics: Aged; Blood Platelets; Cell Communication; Coronary Disease; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Female; Hemostasis; Humans; Male; Middle Aged; NG-Nitroarginine Methyl Ester; Platelet Aggregation; Reactive Oxygen Species; Tyrosine; Xanthine; Xanthine Oxidase | 2012 |
Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial).
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Elective Surgical Procedures; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Premedication; Stents; Ticlopidine; Tirofiban; Troponin T; Tyrosine | 2002 |
Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Infusions, Intravenous; Male; Middle Aged; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Coronary Disease; Coronary Vessels; Female; Humans; Incidence; Male; Middle Aged; Platelet Aggregation Inhibitors; Severity of Illness Index; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, an
Topics: Abciximab; Acute Disease; Aged; Amino Acid Chloromethyl Ketones; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Citric Acid; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Kinetics; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine | 2002 |
Effects of renal insufficiency on early invasive management in patients with acute coronary syndromes (The TACTICS-TIMI 18 Trial).
Topics: Acute Disease; Aged; Angina, Unstable; Cardiac Catheterization; Coronary Disease; Creatinine; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Renal Insufficiency; Risk Factors; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
Topics: Acetates; Acute Disease; Aged; Anticoagulants; Coronary Disease; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Myocardial Revascularization; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Survival Analysis; Tyrosine | 2002 |
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Electrocardiography; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Assessment; Syndrome; Time Factors; Troponin T; Tyrosine | 2003 |
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
Topics: Acetates; Acute Disease; Aged; Arrhythmias, Cardiac; Coronary Disease; Disease-Free Survival; Electrocardiography; Female; Hospitalization; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Survival Analysis; Troponin T; Tyrosine | 2003 |
An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A.
Topics: Acetates; Acute Disease; Aged; Aged, 80 and over; Coronary Disease; Female; Heparin; Humans; Infusions, Intravenous; Logistic Models; Male; Middle Aged; Monitoring, Physiologic; Odds Ratio; Partial Thromboplastin Time; Point-of-Care Systems; Syndrome; Tyrosine | 2002 |
Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; C-Reactive Protein; Coronary Disease; Cytokines; Double-Blind Method; Humans; Inflammation; Interleukin-1; Interleukin-6; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Tirofiban; Troponin; Tumor Necrosis Factor-alpha; Tyrosine | 2003 |
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom.
Topics: Aged; Angina, Unstable; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Hemorrhage; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Patient Admission; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Syndrome; Tirofiban; Treatment Outcome; Tyrosine; United Kingdom | 2003 |
Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
Topics: Abciximab; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Effects of 2 different antiplatelet regimens with abciximab or tirofiban on platelet function in patients undergoing coronary stenting.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Blood Platelets; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Stents; Ticlopidine; Tirofiban; Tyrosine | 2003 |
The effect of glycoprotein IIb/IIIa receptor inhibitor on the microcirculation in patients undergoing high-risk coronary stenting; a prospective, randomized study.
Topics: Aged; Blood Flow Velocity; Coronary Circulation; Coronary Disease; Embolism; Female; Humans; Male; Microcirculation; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Time Factors; Tirofiban; Tyrosine | 2003 |
Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial.
Topics: Aspirin; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
Topics: Acute Disease; Aged; Coronary Disease; Dalteparin; Drug Therapy, Combination; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Treatment Outcome; Tyrosine | 2005 |
Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterization.
Topics: Acetylcholine; Adenosine; Adult; Aged; Cardiac Catheterization; Coronary Circulation; Coronary Disease; Drug Interactions; Endothelin-1; Female; Humans; Male; Middle Aged; Nitrates; Nitric Oxide; Nitrites; Oxygen; Tyrosine; Vasodilator Agents | 2005 |
The effect of tirofiban and clopidogrel pretreatment on outcome of old saphenous vein graft stenting in patients with acute coronary syndromes.
Topics: Acute Disease; Clopidogrel; Coronary Disease; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Saphenous Vein; Stents; Ticlopidine; Tirofiban; Tyrosine | 2005 |
Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Circulation; Coronary Disease; Echocardiography; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Risk Factors; Tirofiban; Troponin I; Tyrosine | 2006 |
The effects of tirofiban on peripheral markers of oxidative stress and endothelial dysfunction in patients with acute coronary syndromes.
Topics: Acute Disease; Aged; Biomarkers; Coronary Disease; Endothelium; Female; Humans; Male; Middle Aged; Neutrophils; Oxidative Stress; Time Factors; Tirofiban; Tyrosine | 2007 |
Outcome of multivessel coronary intervention in the contemporary percutaneous revascularization era.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Disease; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Survival Rate; Tirofiban; Treatment Outcome; Tyrosine | 2006 |
Utility of a whole blood single platelet counting assay to monitor the effects of tirofiban in patients with acute coronary syndromes scheduled for coronary intervention.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Drug Monitoring; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prospective Studies; Syndrome; Tirofiban; Tyrosine | 2006 |
Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
Topics: Acute Disease; Aged; C-Reactive Protein; Coronary Disease; Female; Follow-Up Studies; Humans; Lipoproteins, LDL; Male; Middle Aged; Prognosis; Risk Factors; Simvastatin; Survival Analysis; Tirofiban; Tyrosine | 2006 |
Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Angiography; Coronary Disease; Double-Blind Method; Female; Graft Occlusion, Vascular; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Reoperation; Research Design; Risk Factors; Saphenous Vein; Survival Analysis; Tirofiban; Treatment Outcome; Tyrosine; Venous Thrombosis | 2007 |
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Tirofiban; Treatment Outcome; Tyrosine | 1996 |
Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Combined Modality Therapy; Coronary Angiography; Coronary Artery Bypass; Coronary Circulation; Coronary Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Recurrence; Reoperation; Tirofiban; Treatment Outcome; Tyrosine | 1998 |
Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.
Topics: Abciximab; Administration, Oral; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Cardiology; Clinical Trials as Topic; Coronary Disease; Double-Blind Method; Embolism; Eptifibatide; Female; Fibrinolytic Agents; Follow-Up Studies; Forecasting; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk; Stents; Structure-Activity Relationship; Tirofiban; Treatment Outcome; Tyrosine | 1999 |
Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cohort Studies; Combined Modality Therapy; Coronary Disease; Cost-Benefit Analysis; Double-Blind Method; Female; Hospital Mortality; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Retreatment; Risk Factors; Tirofiban; Tyrosine; United States | 1999 |
Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management.
Topics: Aged; Biomarkers; Coronary Disease; Creatine Kinase; Female; Fibrinolytic Agents; Heparin; Humans; Infusions, Intravenous; Isoenzymes; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Tirofiban; Troponin I; Troponin T; Tyrosine | 1999 |
Global impairment of coronary blood flow in the setting of acute coronary syndromes (a RESTORE substudy). Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Atherectomy, Coronary; Collateral Circulation; Confidence Intervals; Coronary Circulation; Coronary Disease; Coronary Vessels; Double-Blind Method; Fibrinolytic Agents; Humans; Multivariate Analysis; Myocardial Infarction; Placebos; Platelet Glycoprotein GPIIb-IIIa Complex; Recurrence; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Combining low-molecular-weight heparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: the NICE 3 story. National Investigators Collaborating on Enoxaparin.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Feasibility Studies; Humans; Immunoglobulin Fab Fragments; Injections, Intravenous; North America; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 2000 |
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting.
Topics: Abciximab; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Stents; Tirofiban; Tyrosine | 2001 |
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Odds Ratio; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Secondary Prevention; Survival Rate; Treatment Outcome; Troponin T; Tyrosine | 2001 |
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Tirofiban; Tyrosine | 2001 |
Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Feasibility Studies; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Randomized comparison of ticlopidine and clopidogrel after intracoronary stent implantation in a broad patient population.
Topics: Abciximab; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Coronary Thrombosis; Eptifibatide; Exanthema; Female; Gastrointestinal Diseases; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Neutropenia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Thrombocytopenia; Ticlopidine; Tirofiban; Tyrosine | 2001 |
Elevation in serum troponin I predicts the benefit of tirofiban.
Topics: Acute Disease; Aged; Biomarkers; Coronary Disease; Drug Therapy, Combination; Female; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Risk Factors; Survival Rate; Tirofiban; Troponin I; Tyrosine | 2001 |
An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Biomarkers; Coronary Disease; Creatine Kinase; Creatine Kinase, MB Form; Electrocardiography; Endpoint Determination; Follow-Up Studies; Heparin; Humans; Isoenzymes; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Predictive Value of Tests; Risk Assessment; Survival Analysis; Syndrome; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes.
Topics: Acetates; Acute Disease; Aged; Coronary Disease; Double-Blind Method; Endpoint Determination; Female; Hemorrhage; Humans; Incidence; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Titrimetry; Treatment Outcome; Tyrosine | 2002 |
66 other study(ies) available for tyrosine and Coronary Disease
| Article | Year |
|---|---|
The prognostic value of nitrotyrosine levels in coronary heart disease: long-term evaluation in the Acute Coronary Syndrome Registry Strategy (ERICO study).
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Coronary Disease; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors; Tyrosine | 2019 |
[A large-scale, multicenter, retrospective study on efficacy of bivalirudin use during peri-percutaneous coronary intervention period for Chinese patients with coronary heart disease].
Topics: Aged; China; Coronary Disease; Female; Hemorrhage; Heparin; Hirudins; Humans; Male; Peptide Fragments; Percutaneous Coronary Intervention; Recombinant Proteins; Retrospective Studies; Stroke; Tirofiban; Tyrosine | 2016 |
Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; C-Reactive Protein; Case-Control Studies; CD40 Ligand; Coronary Disease; Cross-Sectional Studies; Female; Humans; Inflammation Mediators; Kidney Failure, Chronic; Lipids; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pilot Projects; Protein Carbonylation; Renal Dialysis; Tyrosine; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2008 |
Platelet inhibition with tirofiban early during percutaneous coronary intervention: dosing revisited.
Topics: Cardiac Catheterization; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Radiology, Interventional; Tirofiban; Tyrosine | 2002 |
Immunocytochemical evidence for inducible nitric oxide synthase and cyclooxygenase-2 expression with nitrotyrosine formation in human hibernating myocardium.
Topics: Angiotensin-Converting Enzyme Inhibitors; Biopsy; Coronary Disease; Cyclooxygenase 2; Diuretics; Echocardiography; Humans; Immunohistochemistry; Isoenzymes; Membrane Proteins; Middle Aged; Myocardial Stunning; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Prostaglandin-Endoperoxide Synthases; Tyrosine | 2002 |
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
Topics: Blood Coagulation Tests; Blood Platelets; Coronary Disease; Female; Fibrinolytic Agents; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Glycoprotein GPIIb-IIIa Complex; Time Factors; Tirofiban; Tyrosine | 2002 |
Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban.
Topics: Coronary Disease; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Radioimmunoassay; Tirofiban; Tyrosine | 2003 |
Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Linear Models; Logistic Models; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Risk Factors; Safety; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.
Topics: Abciximab; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Drug Monitoring; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Linear Models; Peptides; Platelet Aggregation Inhibitors; Point-of-Care Systems; Predictive Value of Tests; Tirofiban; Treatment Outcome; Tyrosine; Whole Blood Coagulation Time | 2003 |
A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Coronary Thrombosis; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Multivariate Analysis; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2003 |
Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
Topics: Angioplasty, Balloon, Coronary; Blood Coagulation Tests; Coronary Disease; Female; Fibrinolytic Agents; Hemorrhage; Heparin; Humans; Male; Middle Aged; Tirofiban; Tyrosine | 2003 |
Retroperitoneal hematoma following tirofiban and enoxaparin coadministration in a patient with acute coronary syndrome.
Topics: Acute Disease; Aged; Anticoagulants; Coronary Disease; Enoxaparin; Hematoma; Humans; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Retroperitoneal Space; Tirofiban; Tyrosine | 2003 |
Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement.
Topics: Aged; Cardiac Catheterization; Chi-Square Distribution; Coronary Angiography; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Retrospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th
Topics: Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Combined Modality Therapy; Comorbidity; Coronary Disease; Female; Hospitalization; Humans; Life Tables; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents; Survival Analysis; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine | 2004 |
Tirofiban and eptifibatide treatment of patients presenting with acute coronary syndrome with non-ST segment elevation.
Topics: Acute Disease; Aged; Aged, 80 and over; Biomarkers; Coronary Disease; Drug Utilization Review; Electrocardiography; Eptifibatide; Female; Formularies, Hospital as Topic; Humans; Inpatients; Male; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Retrospective Studies; Tirofiban; Tyrosine | 2004 |
Characterization and metal affinity of Tirofiban, a pharmaceutical compound used in acute coronary syndromes.
Topics: Coronary Disease; Hydrogen Bonding; Hydrogen-Ion Concentration; Ligands; Magnetic Resonance Spectroscopy; Metals; Models, Molecular; Platelet Aggregation Inhibitors; Potentiometry; Spectrophotometry, Infrared; Tirofiban; Tyrosine | 2004 |
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Hospitals, Veterans; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Middle Aged; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Retrospective Studies; Risk Factors; Tirofiban; Tyrosine | 2004 |
Restoration of normal coronary flow with tirofiban by intracoronary administration for no-reflow phenomenon after stent deployment.
Topics: Aged; Coronary Circulation; Coronary Disease; Humans; Infusions, Intravenous; Male; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Syndrome; Tirofiban; Tyrosine | 2005 |
Safety of tirofiban therapy in korean patients with acute coronary syndrome.
Topics: Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Coronary Disease; Drug Evaluation; Female; Humans; Korea; Male; Middle Aged; Platelet Aggregation Inhibitors; Retrospective Studies; Syndrome; Tirofiban; Tyrosine | 2005 |
Delayed stenting of a thrombotic saphenous vein graft after intravenous tirofiban pretreatment.
Topics: Aged; Coronary Disease; Humans; Male; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Saphenous Vein; Stents; Thrombosis; Tirofiban; Tyrosine | 2006 |
Two distinct subgroups of tirofiban-induced thrombocytopenia exist due to drug dependent antibodies that cause platelet activation and increased ischaemic events.
Topics: Acute Disease; Aged; Aged, 80 and over; Autoantibodies; Coronary Disease; Female; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purpura, Thrombocytopenic, Idiopathic; Tirofiban; Tyrosine | 2005 |
Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target?
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Syndrome; Tirofiban; Tyrosine; Venous Thrombosis | 2007 |
Influence of preparative procedures on assay of platelet function and apparent effects of antiplatelet agents.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Benzothiazoles; Blood Platelets; Coronary Disease; Crotalid Venoms; Flow Cytometry; Fluorescent Dyes; Hemostatics; Humans; Lectins, C-Type; Platelet Activating Factor; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Glycoprotein GPIIb-IIIa Complex; Quinolines; Thrombin; Tirofiban; Tyrosine | 2007 |
Changes of serum tyrosine in Yin-deficient patients with coronary heart disease.
Topics: Adult; Aged; Coronary Disease; Female; Humans; Male; Medicine, Chinese Traditional; Medicine, East Asian Traditional; Middle Aged; Tyrosine | 1984 |
Myocardial proteolysis during acute myocardial ischaemia.
Topics: Animals; Coronary Disease; Dogs; Female; Hydrolysis; In Vitro Techniques; Leupeptins; Male; Myocardium; Proteins; Tyrosine | 1983 |
In search of a superaspirin for the heart.
Topics: Abciximab; Acetates; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 1997 |
17beta-estradiol inhibits apoptosis of endothelial cells.
Topics: Animals; Apoptosis; Cattle; Cell Adhesion Molecules; Cell Movement; Cells, Cultured; Coronary Disease; Endothelium, Vascular; Estradiol; Female; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Microscopy, Electron; Phosphorylation; Postmenopause; Protein-Tyrosine Kinases; Tyrosine | 1997 |
Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris.
Topics: Angina, Unstable; Atherectomy, Coronary; Coronary Disease; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phosphorylation; Receptors, Platelet-Derived Growth Factor; Recurrence; Regression Analysis; Risk Factors; Statistics, Nonparametric; Tyrosine | 1998 |
Inducible nitric oxide synthase expression in smooth muscle cells and macrophages of human transplant coronary artery disease.
Topics: Adult; Child; Child, Preschool; Coronary Artery Disease; Coronary Disease; Coronary Vessels; Endothelium, Vascular; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Enzymologic; Heart Transplantation; Humans; In Situ Hybridization; Macrophages; Male; Middle Aged; Muscle, Smooth, Vascular; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; RNA, Messenger; Tyrosine | 1998 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1998 |
Two i.v. antiplatelet agents marketed for coronary disease.
Topics: Coronary Disease; Drug Approval; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 1998 |
Two new antiplatelet drugs for angioplasty and acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Premedication; Syndrome; Tirofiban; Tyrosine | 1998 |
Safety and effectiveness of inhaled nitric oxide and tirofiban for acute coronary syndromes: a report from the cardiovascular and renal advisory panel of the food and drug administration.
Topics: Acute Disease; Administration, Inhalation; Coronary Disease; Humans; Nitric Oxide; Platelet Aggregation Inhibitors; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration; Vasodilator Agents | 1998 |
Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment.
Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Antibodies, Monoclonal; Anticoagulants; Clinical Trials as Topic; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Infusions, Parenteral; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombosis; Tirofiban; Tyrosine | 1999 |
A symposium: safety issues concerning the use of glycoprotein IIb-IIIa inhibitors in the management of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Myocardial Ischemia; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Safety; Tirofiban; Tyrosine | 1999 |
[GP-IIb/IIIa antagonists expand the anti thrombotic therapy of acute coronary syndromes. Satellite symposium during the 21st Congress of the European Society of Cardiology. Barcelona, August 1999].
Topics: Acute Disease; Coronary Disease; Drug Combinations; Fibrinolytic Agents; Heparin; Humans; Myocardial Infarction; Thrombolytic Therapy; Tirofiban; Tyrosine | 1999 |
Therapeutic efficiency of tirofiban in acute coronary syndromes.
Topics: Aged; Coronary Disease; Fibrinolytic Agents; Humans; Predictive Value of Tests; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2000 |
Therapeutic efficiency of tirofiban in acute coronary syndromes.
Topics: Coronary Disease; Fibrinolytic Agents; Humans; Risk Factors; Tirofiban; Treatment Outcome; Troponin I; Troponin T; Tyrosine | 2000 |
Beyond aspirin: how glycoprotein inhibitors ease acute coronary syndromes.
Topics: Abciximab; Acute Disease; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Middle Aged; Nursing Assessment; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 1999 |
Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes.
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Coronary Disease; Dose-Response Relationship, Drug; Eptifibatide; Heparin; Humans; Immunoglobulin Fab Fragments; Kinetics; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thromboplastin; Tirofiban; Tyrosine | 2000 |
Drip and ship: a new strategy for the treatment of acute coronary syndromes.
Topics: Abciximab; Acute Disease; Adult; Aged; Aged, 80 and over; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Aspirin; Clinical Protocols; Coronary Angiography; Coronary Disease; Electrocardiography; Female; Fibrinolytic Agents; Heparin; Hospitalization; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Nitrates; Platelet Aggregation Inhibitors; Prospective Studies; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2000 |
Timing of coronary stent thrombosis in patients treated with prophylactic tirofiban.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prosthesis Failure; Retrospective Studies; Stents; Time Factors; Tirofiban; Tyrosine | 2000 |
Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
Topics: Angina, Unstable; Anticoagulants; Coronary Disease; Creatine Kinase; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heart Failure; Heparin; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Regression Analysis; Risk Factors; Statistics, Nonparametric; Tirofiban; Treatment Outcome; Troponin I; Tyrosine | 2000 |
Platelets and coronary intervention: some practical precautions.
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Drug Monitoring; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Incidence; Male; Peptides; Platelet Aggregation Inhibitors; Prognosis; Risk Assessment; Thrombocytopenia; Tirofiban; Tyrosine | 2000 |
[Therapy of acute coronary syndrome with glycoprotein IIb/IIIa antagonists].
Topics: Abciximab; Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Atherectomy; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Eptifibatide; Fibrinolytic Agents; Heparin; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Tirofiban; Tyrosine; United States; United States Food and Drug Administration | 2000 |
[Update on tirofiban].
Topics: Coronary Disease; France; Humans; Patient Selection; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Practice Guidelines as Topic; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[Risk stratification in acute coronary syndrome].
Topics: Abciximab; Acute Disease; Angina, Unstable; Antibodies, Monoclonal; Anticoagulants; Biomarkers; Clinical Trials as Topic; Coronary Disease; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Nadroparin; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Retrospective Studies; Risk Factors; Syndrome; Terminology as Topic; Tirofiban; Troponin I; Troponin T; Tyrosine | 2001 |
Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab.
Topics: Abciximab; Adult; Aged; Antibodies, Monoclonal; Coronary Disease; Female; Fibrinogen; Flow Cytometry; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2001 |
Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Atherectomy, Coronary; Coronary Disease; Female; Heparin; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptide Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Prothrombin; Stents; Thrombin; Tirofiban; Tyrosine; Whole Blood Coagulation Time | 2001 |
Future trials of antiplatelet agents in cardiac ischemia.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Immunoglobulin Fab Fragments; Placebos; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Research Design; Stents; Tirofiban; Tyrosine | 2001 |
Optimal treatment of acute coronary syndromes--an evolving strategy.
Topics: Abciximab; Acute Disease; Algorithms; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Tirofiban; Tyrosine | 2001 |
Glycoprotein IIb/IIIa inhibitors: more different than alike?
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Eptifibatide; Humans; Immunoglobulin Fab Fragments; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2001 |
Tirofiban therapy does not increase the risk of hemorrhage after emergency coronary surgery.
Topics: Blood Coagulation; Blood Transfusion; Coronary Disease; Drug Administration Schedule; Drug Monitoring; Emergencies; Hemorrhage; Humans; Infusions, Intravenous; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
A comparison of total hospital costs for percutaneous coronary intervention patients receiving abciximab versus tirofiban.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Coronary Disease; Female; Health Status; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Insurance, Health; Length of Stay; Male; Middle Aged; Models, Econometric; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2001 |
Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban).
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidogrel; Coronary Disease; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Stents; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2001 |
[Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban].
Topics: Coronary Disease; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Syndrome; Time Factors; Tirofiban; Tyrosine | 2001 |
Cost effectiveness of invasive strategy in unstable coronary disease--what are we waiting for?
Topics: Coronary Artery Bypass; Coronary Artery Disease; Coronary Disease; Cost-Benefit Analysis; Europe; Fibrinolytic Agents; Health Care Costs; Humans; Platelet Glycoprotein GPIIb-IIIa Complex; Tirofiban; Tyrosine | 2002 |
Cost implications of routine tirofiban use in the management of acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Coronary Disease; Eligibility Determination; Female; Health Care Costs; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Random Allocation; Syndrome; Tirofiban; Tyrosine | 2001 |
Platelet glycoprotein IIb/IIIa inhibitor effect examined in 2 studies.
Topics: Acetates; Acute Disease; Angina, Unstable; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Eptifibatide; Humans; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prognosis; Syndrome; Treatment Outcome; Tyrosine | 2002 |
Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Blood Coagulation Tests; Coronary Disease; Drug Therapy, Combination; Fibrinogen; Heparin; Humans; Immunoglobulin Fab Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Tirofiban; Tyrosine | 2002 |
Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors.
Topics: Abciximab; Aged; Antibodies, Monoclonal; Cardiac Catheterization; Coronary Disease; Eptifibatide; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sex Factors; Stents; Tirofiban; Treatment Outcome; Tyrosine | 2002 |
The TARGET trial: hit or miss?
Topics: Abciximab; Antibodies, Monoclonal; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Stents; Tirofiban; Tyrosine | 2002 |
[Hyperhomocystinemia and 677C T methylenetetrahydrofolate reductase polymorphism as a cardiovascular risk factor in childhood].
Topics: Adolescent; Age Factors; Child; Child, Preschool; Coronary Disease; Cross-Sectional Studies; Cytosine; Female; Humans; Hyperhomocysteinemia; Male; Methylenetetrahydrofolate Dehydrogenase (NADP); Polymorphism, Genetic; Tyrosine | 2002 |
Control of ventricular fibrillation after coronary artery occlusion via intracerebroventricular injections.
Topics: Animals; Brain; Coronary Disease; Drug Combinations; Female; Injections, Intraventricular; Isoproterenol; Male; Norepinephrine; Propranolol; Swine; Tyrosine; Ventricular Fibrillation | 1992 |
Lactate dehydrogenase and aspartate aminotransferase isoenzymes in normal and hypertrophic human heart.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Coronary Disease; Heart Valve Diseases; Humans; Hypertension; Isoenzymes; L-Lactate Dehydrogenase; Mitochondria, Muscle; Myocardium; Rats; Species Specificity; Tyrosine | 1970 |